Phase 1 trial lisocabtagene maraleucel, a CD19-directed CAR-T for frontline PCNSL.

This study evaluates the safety and efficacy of lisocabtagene maraleucel as first-line treatment in transplant-ineligible adults with Primary CNS Lymphoma in investigational and expansion arms. Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, it represents a novel approach in CAR-T therapy for this indication.